Claims for Patent: 6,740,522

Summary for Patent: 6,740,522

Title:	Antibodies against ligand for receptor activator of NF-kB
Abstract:	Provided herein are antibodies that bind human RANKL polypeptides.
Inventor(s):	Anderson; Dirk M. (Seattle, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	09/865,363
Patent Claims:	1. A purified antibody that binds with higher affinity to a human RANKL polypeptide as shown in SEQ ID NO. 13 than to a murine RANKL polypeptide as shown in SEQ ID NO. 11. 2. An antibody according to claim 1 which is a monoclonal antibody. 3. A method of producing a monoclonal antibody according to claim 2, said method comprising culturing a cloned hybridoma cell that produces said antibody. 4. A method of producing a monoclonal antibody according to claim 2, said method comprising injecting into the peritoneal cavity of a rodent a cloned hybridoma cell that produces said antibody. 5. A cloned hybridoma cell that produces a monoclonal antibody according to claim 2. 6. A composition comprising an antibody according to claim 1. 7. A purified antibody that binds with higher affinity to a human RANKL polypeptide than to a murine RANKL polypeptide according to SEQ ID NO. 11, wherein said human RANKL polypeptide is selected from the group consisting of: a) a RANKL polypeptide comprising amino acids 69-313 of SEQ ID NO. 13; b) a RANKL polypeptide comprising amino acids 1-162 of SEQ ID NO. 13; c) a RANKL polypeptide comprising amino acids 162-313 of SEQ ID NO: 13; d) a RANKL polypeptide comprising amino acids 138-317 of SEQ ID NO:13; and e) a RANKL polypeptide comprising amino acids x to y of SEQ ID NO. 13, wherein x is an amino terminal amino acid between 69 and 162 of SEQ ID NO: 13, and y is a carboxy terminal amino acid between 313 and 317 of SEQ ID NO: 13. 8. An antibody according to claim 7 which is a monoclonal antibody. 9. An antibody according to claim 8, wherein the RANKL polypeptide comprises amino acids 69-313 of SEQ ID NO. 13. 10. An antibody according to claim 8, wherein the RANKL polypeptide comprises amino acids 1-162 of SEQ ID NO. 13. 11. An antibody according to claim 8, wherein the RANKL polypeptide comprises amino acids 162-313 of SEQ ID NO. 13. 12. An antibody according to claim 8, wherein the RANKL polypeptide comprises amino acids 138-317 of SEQ ID NO: 13. 13. A composition comprising an antibody according to claim 8. 14. A purified antibody that binds to a human RANKL polypeptide as shown in SEQ ID NO. 13, but that does not bind to a murine RANKL polypeptide as shown in SEQ ID NO. 11. 15. A purified antibody that binds with higher affinity to a human RANKL polypeptide as shown in SEQ ID NO. 13 than to a murine RANKL polypeptide as shown in SEQ ID NO: 11, wherein said antibody is generated by a method comprising immunizing with a RANKL polypeptide comprising amino acids x to y of SEQ ID NO: 13, wherein x is an amino terminal amino acid between 69 and 162 of SEQ ID NO: 13, and y is a carboxy terminal amino acid between 313 and 317 of SEQ ID NO: 13. 16. A method for generating an antibody, said method comprising immunizing with a RANKL polypeptide selected from the group consisting of: a) a polypeptide comprising amino acids 1-317 of SEQ ID NO. 13; b) a polypeptide comprising amino acids 69-313 of SEQ ID NO. 13; c) a polypeptide comprising amino acids 1-162 of SEQ ID NO. 13; d) a polypeptide comprising amino acids 162-313 of SEQ ID NO. 13; e) a polypeptide comprising amino acids 138-317 of SEQ ID NO. 13; and f) a polypeptide comprising amino acids x to y of SEQ ID NO. 13, wherein x is an amino terminal amino acid between 69 and 162 of SEQ ID NO. 13, and y is a carboxy terminal amino acid between 313 and 317 of SEQ ID NO. 13. 17. A method for preparing an antibody according to claim 16, wherein the antibody is elicited by immunizing with a RANKL polypeptide comprising amino acids 1-317 of SEQ ID NO. 13. 18. A method for preparing an antibody according to claim 16, wherein the antibody is elicited by immunizing with a RANKL polypeptide comprising amino acids 69-313 of SEQ ID NO. 13. 19. A method for preparing an antibody according to claim 16, wherein the antibody is elicited by immunizing with a RANKL polypeptide comprising amino acids 1-162 of SEQ ID NO. 13. 20. A method for preparing an antibody according to claim 16, wherein the antibody is elicited by immunizing with a RANKL polypeptide comprising amino acids 162-313 of SEQ ID NO. 13. 21. A method for preparing an antibody according to claim 16, wherein the antibody is elicited by immunizing with a RANKL polypeptide comprising amino acids 138-317 of SEQ ID NO. 13. 22. A method for preparing an antibody according to claim 16, wherein the antibody is elicited by immunizing with a RANKL polypeptide comprising amino acids x to y of SEQ ID NO. 13, wherein x is an amino terminal amino acid between 69 and 162 of SEQ 11) NO:13, and y is a carboxy terminal amino acid between 313 and 317 of SEQ ID NO. 13.

Details for Patent 6,740,522

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 01, 2010	6,740,522	2016-12-23
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010	6,740,522	2016-12-23

International Patent Family for US Patent 6,740,522

Country	Patent Number	Estimated Expiration
United States of America	8715683
United States of America	8569456
United States of America	8377690
World Intellectual Property Organization (WIPO)	9958674
World Intellectual Property Organization (WIPO)	9828426
World Intellectual Property Organization (WIPO)	9828424